Monthly Archives: October 2022

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (MAIA, the Company), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that it will present the results of a study of the anticancer agent 6-thio-dG (THIO) in hepatocellular carcinoma (HCC) in vitro and in vivo models at the EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics. The symposium is taking place Oct. 26-28, 2022, in Barcelona, Spain.

The data to be presented outline high anticancer activity of THIO in HCC cancer cells. Notably, sequential administration of THIO followed by cemiplimab (cemi) demonstrated enhanced antitumor efficacy, including complete responses, in a syngeneic immunocompetent HCC mouse model, in comparison with either single agent used alone. Moreover, the treated tumor-free mice demonstrated a complete rejection of the same tumor type cells upon re-challenge: anticancer immune memory was confirmed.

MAIA received an Orphan Drug Designation from the US FDA for the treatment of HCC with THIO earlier in 2022. HCC currently makes up around 90% of liver cancer cases; by 2025, the global incidence of liver cancer is expected to eclipse 1 million cases.1

Presentation details:

Additional meeting information is available on ENA's website.

About THIO

THIO (6-thio-dG or 6-thio-2-deoxyguanosine) is a telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC), in sequential administration with cemiplimab (Libtayo), a PD-1 inhibitor developed by Regeneron. Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies. THIO is being developed as a second or higher line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Companys lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of patients with telomerase-positive cancers. For more information, please visit http://www.maiabiotech.com.

1 Llovet, J.M., Kelley, R.K., Villanueva, A. et al. Hepatocellular carcinoma. Nat Rev Dis Primers 7, 6 (2021). https://doi.org/10.1038/s41572-020-00240-3

Forward Looking Statements

This press release includes forward-looking statements including, but not limited to, statements related to the closing of the offering and the expected use of proceeds, development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on managements current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, that the risks that prior clinical and preclinical results may not be replicated, and risks associated with the current coronavirus pandemic. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.

See the original post here:
MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Business Wire

China has very small farms; there hasnt been a lot of infrastructure put in place in terms of knowledge or solid assets. Now Syngenta is enabling them with agronomists and digital infrastructure.

When it comes to Beijings technological ambitions, high profile hardware like semiconductors and electric vehicles tend to dominate global headlines. But in China, where almost 20 percent of the global population lives on 8.5 percent of the worlds arable land, finding innovative ways to reap more food from every hectare of seeds sown has long been one of the governments highest priorities.

Chinese agriculture and food demand is in inherent conflict, says Wendong Zhang, an assistant professor at Cornell Universitys Dyson School of Applied Economics and Management and a specialist in Chinas agricultural development. China wont be able to have more land. They wont be able to have better quality soil. The thing they can control is technology.

Beijings realization that technology would be key to increasing its food self-sufficiency is what made Syngenta such a valuable target for ChemChina. Syngenta, after all, is the world-leader in crop protection products and globally the number three producer of seeds, including selectively-bred hybrids and genetically modified seeds. Alongside rivals like Germanys Bayer and Americas Corteva (formerly DowDupont), the company is pushing the boundaries of seed genomics using CRISPR-Cas9, a tool that allows researchers to tweak the genetics of living organisms.

Emboldened by its ownership of Syngenta, China seems to be crossing the rubicon when it comes to high-tech agriculture. Officials are now calling cutting-edge seeds agriculture microchips, according to Chinese state media.

And safety approvals for GM seeds appear to be speeding up: in early 2022, Beijings Ministry of Agriculture and Rural Affairs (MARA) granted safety certificates to three Syngenta GM corn seeds as well as a seed from the domestic firm Hangzhou Ruifeng Bio-Tech Company and several others from Chinese universities. In June, MARA also released guidelines, for the first time, that could pave the way for companies to begin commercial planting of GM products.

And with its high-profile Shanghai listing, Syngenta might help the Chinese government out of a dilemma of its own making: convincing the general public that GMOs are safe. At the very least, the company cant be viewed as a trojan horse for U.S. bioweapons. Syngentas MAP program has even introduced QR codes on food packaging so consumers can scan their food and see a photo of the Chinese farmer who grew it.

To help itself out of its GMO bind, Beijing is also positioning its efforts in direct gene editing as a kind of technological leapfrogging these newer engineering methods do not require the introduction of foreign DNA, unlike todays genetic modification, in which bacteria from one organism is transplanted into another ( la the Bt genes added into the corn genome). As [Shane] Thomas, the analyst, notes, the industry as a whole is moving towards this more precise kind of genetic tweaking.

This is an excerpt. Read the original post here

More:
China's Syngenta pushes the edge: Can technology-driven agriculture promote a new view of sustainable farming to a world still wary of biotechnology?...

Image Source: FreeImages

The global bio-economy is growing at an incredible pace, with plenty of opportunity for investors. The biotech industry in general, and biotech stocks specifically, provide a lot of potential for long-term returns. Biotechnology is the application of biological principles to create new products and services. It has many applications, from agricultural uses to medical research and drug development. As a result, the biotechnology sector has grown strongly as other industries adopt its technologies and invest in related ventures and partnerships.Investors looking to capitalize on this growth need to understand which companies are leading the way. Fortunately, there are several great biotechnology stocks that can offer excellent returns in the coming years. Here are some of the top opportunities currently available:

Global Blood Therapeutics (GBT) is an emerging biotechnology company focused on creating therapies for rare blood diseases.GBTs lead product, Prophage, is a gene therapy designed to treat patients with beta-thalassemia, a rare inherited blood disorder.drug has been granted Orphan Drug Designation by the FDA and designation as a Breakthrough Therapy from the FDAs Oncology Drug Review Committee.GBT has also partnered with Galapagos NV, one of the top gene-therapy companies in the world. The company has a Phase 3 development program for Prophage, with a goal to complete registration in the next few years. With a potential blockbuster drug on the table, GBT has the potential to grow very quickly.

BridgeBio Pharma (BBIO) is a clinical-stage biopharmaceutical company focused on bringing new therapies to patients suffering from rare diseases.BBIO has a robust product pipeline, with several therapies in Phase 1 and 2 clinical trials. The company is also in the pre-clinical development stages of several promising new therapies. BBIOs main product candidates are focused on iron-related disorders, including an iron chelating agent for patients with rare blood diseases.BBIO has partnered with some of the largest companies in the world, including The Medicines Company, Celgene, and Bayer.BBIOs therapies are currently in Phase 2 development and are expected to advance into Phase 3 in the next few years. When these drugs are approved, BBIO will be poised for growth.

SIGA Technologies (SIGA) is a biopharmaceutical company focused on creating vaccines and medicines for infectious diseases.SIGA has a robust product pipeline focused on viral diseases, including respiratory and viral hemorrhagic fever diseases. The company is currently investing in three main products.First is a universal flu vaccine designed to address issues with current flu vaccines. SIGAs universal flu vaccine is administered as a nasal spray, has no adjuvant, and is designed to provide constant immunity to the most common flu strains.Second is an Ebola vaccine designed to treat patients infected with the Ebola virus. The vaccine has been in development since 2003, when the Ebola outbreak in Africa began.Third is a therapeutic vaccine designed to treat dengue fever. The vaccine has completed Phase 1/2 trials and is expected to advance into Phase 3 trials in the next few years.

Ninety (NOVT) is a biotechnology company focused on creating therapies for the eye.NOVT is currently developing a first-in-kind therapy called a corneal scarring therapy that could replace corneal transplants in some patients.The company is expected to advance this product into Phase 3 trials in the next few years. Once the treatment is approved, it could become a huge product for NOVT.While the companys main product remains in development, it is also investing in other eye-related therapies. NOVT has a partnership with Galapagos NV to develop gene therapies for retinal diseases. The company is also developing a novel combination therapy for glaucoma.

Biotechnology is a growing industry that is expected to continue to see strong growth. The sector is also expected to see some strong mergers and acquisitions, providing another avenue for growth.Investors looking for growth in the biotechnology industry can consider investing in any of the top biotechnology stocks above. These companies are all poised for growth over the next several years, and could offer excellent returns for investors.

Image Source: FreeImages

The global economy is growing incredibly, with plenty of opportunities for investors. The biotech industry, in general, and biotech stocks, provide a lot of potential for long-term returns. Biotechnology is the application of biological principles to create new products and services. It has many applications, from agricultural uses to medical research and drug development. As a result, biotechnology has grown strongly as other industries adopt its technologies and invest in related ventures and partnerships. Investors looking to capitalize on this growth need to understand which companies are leading the way. Fortunately, several great biotechnology stocks can offer excellent returns in the coming years. Here are some of the top opportunities currently available:

Global Blood Therapeutics (GBT) is an emerging biotechnology company focused on creating therapies for rare blood diseases.GBTs lead product, Prophage, is a gene therapy designed to treat patients with beta-thalassemia, a rare inherited blood disorder. The drug has been granted Orphan Drug Designation by the FDA and designated as a Breakthrough Therapy by the FDAs Oncology Drug Review Committee.GBT has also partnered with Galapagos NV, one of the top gene-therapy companies in the world. In addition, the company has a Phase 3 development program for Prophage, to complete registration in the next few years. With a potential blockbuster drug on the table, GBT has the potential to grow very quickly.

BridgeBio Pharma (BBIO) is a clinical-stage biopharmaceutical company focused on bringing new therapies to patients suffering from rare diseases.BBIO has a robust product pipeline, with several therapies in Phase 1 and 2 clinical trials. The company is also in the pre-clinical development stages of several promising new therapies. BBIOs main product candidates are focused on iron-related disorders, including an iron chelating agent for patients with rare blood diseases.BBIO has partnered with some of the largest companies in the world, including The Medicines Company, Celgene, and Bayer.BBIOs therapies are currently in Phase 2 development and are expected to advance into Phase 3 in the next few years. When these drugs are approved, BBIO will be poised for growth.

SIGA Technologies (SIGA) is a biopharmaceutical company focused on creating vaccines and medicines for infectious diseases.SIGAs robust product pipeline focused on viral diseases, including respiratory and viral hemorrhagic fever. The company is currently investing in three main products:

The vaccine has completed Phase 1/2 trials and is expected to advance into Phase 3 trials in the next few years.

Ninety (NOVT) is a biotechnology company focused on creating therapies for the eye.NOVT is currently developing a first-in-kind therapy called corneal scarring therapy that could replace corneal transplants in some patients. The company is expected to advance this product into Phase 3 trials in the next few years. Once approved, the treatment could become a huge product for NOVT. While the companys main product remains developing, it is also investing in other eye-related therapies. For example, NOVT partnered with Galapagos NV to develop gene therapies for retinal diseases. In addition, the company is also developing a novel combination therapy for glaucoma.

Biotechnology is a growing industry that is expected to continue to see strong growth. The sector is also expected to see strong mergers and acquisitions, providing another avenue for growth. Investors looking for growth in the biotechnology industry can consider investing in any of the top biotechnology stocks above. These companies are poised for growth over the next several years and could offer excellent returns for investors.

Go here to see the original:
The Best Biotechnology Stocks to Invest in Right Now - Best Stocks

England is in crisis. They lost a beloved figurehead this month but for decades prior were losing scientific ground. If you look for the home of the modern organic food and anti-vaccine movements, you find their nexus in 1990s England.

The primary royal behind those beliefs is now King Charles III.

In order to manage the $28 billion he inherits (tax-free, paying taxes only applies to peasants in England)(1) he will have to give his $1.5 billion estate to his son, the new Prince of Wales, William (also tax free) but the Prince is not only taking over during a time when Brits are wondering why they still care about a throne that hasnt been relevant in hundreds of years, he is taking over at a time when being anti-science is no longer fashionable for progressive elites.

Though it was recently the darling of the intelligentsia, and Prince Charles longed to belong in that circle, anti-vaccine sentiments have become proletariat since COVID-19. The war on science when it comes to food harms a lot more people worldwide each year than the pandemic did. Hundreds of thousands of kids could stop going blind each year with Golden Rice but elites like King Charles III give money to groups that block its implementation.

Prince William could start to gain back some credibility for the family by jettisoning the organic food fetish of his father. Organic food, like the anti-vaccine movement, is a relic of 1990s England. Dr. Andrew Wakefield set off the modern anti-vaccine craze the same way that English environmental activists set off the Frankenfood one. Now supplements, wellness, and organic are all giant businesses based on exploitation of famous names who wanted to impress their elite friends

The world should have passed the anti-vaccine and anti-food movement by but they persist in large part because of the new British monarch and his quasi-American royalty of American Democrats counterpart, Robert F. Kennedy, Jr.(2)

Its easy to embrace science, especially in light of their history making changes when it was needed. They changed their name to Windsor from Saxe-Coburg and Gotha during World War I to help commoners forget the British royal family is German during a time that Germany was shooting at English men in Europe. Given that public relations success, they can certainly change their tune when it comes to science.

Perhaps due to an infusion of new blood outside the shockingly limited pool drawn from during the 19th and 20th centuries, Prince William seems to be a more genetically gifted thinker than his father. He can show it by embracing the modern world, where food and medicine are embraced.(3)

He doesnt actually have to divest from the farm, that is just me getting attention in a title. It is enough if he acknowledges that having peasants toil for his carrots only using specially labeled toxic pesticides is a pastime for the rich, and not a way to feed the world.

(1) The same way California Governor Gavin Newsom doesnt want people who make over $2 million each year to pay higher taxes to subsidize the electric cars the Governor insists Uber drivers need to buy. High taxes are for the middle class and the poor, not the donors he will need in order to fail running for President in 2024.

(2) Nothing looks more hypocritical than people on the left in England and the US suddenly endorsing vaccines when just two years ago they opposed them. It instead reeks of politics, and politics need to be a no-no for the new generation of British royals, lest they be relegated to the name recognition of the Queen of the Netherlands, whoever that is.

(3) and not just engage in publicity stunts about energy costs that are squarely the blame of the government his father now seeks to lead.

Hank Campbell founded Science 2.0 in 2006, and writes for USA Today, Wall Street Journal, CNN, and more. His first book,Science Left Behind,was the #1 bestseller on Amazon for environmental policy books. Follow Hank on Twitter@HankCampbell

A version of this article was originally posted atScience 2.0and is reposted here with permission. Science 2.0 can be found on Twitter@science2_0

The rest is here:
Viewpoint: Will King Charles abandon his kooky ideas about agriculture and help accelerate Britain's embrace of sustainable biotechnology tools? -...